Patient response per IRF by baseline disease subtype and stage per investigator in the ITT population
| . | Patients, n (%) . | |||||||
|---|---|---|---|---|---|---|---|---|
| . | Brentuximab vedotin (n = 64) . | Physician’s choice (n = 64) . | ||||||
| . | Total . | ORR4 . | ORR . | CR . | Total . | ORR4 . | ORR . | CR . |
| MF | 48 (75) | 24 (50) | 31 (65) | 5 (10) | 49 (77) | 5 (10) | 8 (16) | 0 |
| Stage | ||||||||
| IA-IIA | 15 (31) | 6 (40) | 8 (53) | 1 (7) | 18 (37) | 4 (22) | 5 (28) | 0 |
| IIB | 19 (40) | 12 (63) | 13 (68) | 3 (16) | 19 (39) | 1 (5) | 3 (16) | 0 |
| IIIA-IIIB | 4 (8) | 2 (50) | 3 (75) | 0 | 2 (4) | 0 | 0 | 0 |
| IVA | 2 (4) | 2 (100) | 2 (100) | 1 (50) | 9 (18) | 0 | 0 | 0 |
| IVB | 7 (15) | 2 (29) | 4 (57) | 0 | 0 | — | — | — |
| Unknown | 1 (2) | 0 | 1 (100) | 0 | 1 (2) | 0 | 0 | 0 |
| C-ALCL | 16 (25) | 11 (69) | 11 (69) | 6 (38) | 15 (23) | 3 (20) | 5 (33) | 1 (7) |
| Involvement | ||||||||
| Skin only | 9 (56) | 8 (89) | 8 (89) | 4 (44) | 11 (73) | 3 (27) | 5 (45) | 1 (9) |
| Extracutaneous disease | 7 (44) | 3 (43) | 3 (43) | 2 (29) | 4 (27) | 0 | 0 | 0 |
| . | Patients, n (%) . | |||||||
|---|---|---|---|---|---|---|---|---|
| . | Brentuximab vedotin (n = 64) . | Physician’s choice (n = 64) . | ||||||
| . | Total . | ORR4 . | ORR . | CR . | Total . | ORR4 . | ORR . | CR . |
| MF | 48 (75) | 24 (50) | 31 (65) | 5 (10) | 49 (77) | 5 (10) | 8 (16) | 0 |
| Stage | ||||||||
| IA-IIA | 15 (31) | 6 (40) | 8 (53) | 1 (7) | 18 (37) | 4 (22) | 5 (28) | 0 |
| IIB | 19 (40) | 12 (63) | 13 (68) | 3 (16) | 19 (39) | 1 (5) | 3 (16) | 0 |
| IIIA-IIIB | 4 (8) | 2 (50) | 3 (75) | 0 | 2 (4) | 0 | 0 | 0 |
| IVA | 2 (4) | 2 (100) | 2 (100) | 1 (50) | 9 (18) | 0 | 0 | 0 |
| IVB | 7 (15) | 2 (29) | 4 (57) | 0 | 0 | — | — | — |
| Unknown | 1 (2) | 0 | 1 (100) | 0 | 1 (2) | 0 | 0 | 0 |
| C-ALCL | 16 (25) | 11 (69) | 11 (69) | 6 (38) | 15 (23) | 3 (20) | 5 (33) | 1 (7) |
| Involvement | ||||||||
| Skin only | 9 (56) | 8 (89) | 8 (89) | 4 (44) | 11 (73) | 3 (27) | 5 (45) | 1 (9) |
| Extracutaneous disease | 7 (44) | 3 (43) | 3 (43) | 2 (29) | 4 (27) | 0 | 0 | 0 |
One patient in each arm had incomplete staging data and are not included in the table: 1 patient in the brentuximab vedotin arm had a PR, and 1 patient in the physician’s choice arm had no response.